Mercury Biopharmaceutical Corporation (TPEX:6932)

Mercury Biopharmaceutical Income Statement

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	4.96	1.03	2.68	-	-
Revenue Growth (YoY)	380.44%	-61.46%	-	-	-
Cost of Revenue	0.78	0.44	1.51	-	-
Gross Profit	4.18	0.59	1.17	-	-
Selling, General & Admin	25.57	24.91	16.66	2.48	0.21
Research & Development	32.66	21.37	15.41	2.82	-
Operating Expenses	58.23	46.28	32.07	5.3	0.21
Operating Income	-54.04	-45.69	-30.9	-5.3	-0.21
Interest Expense	-0.8	-0.71	-0.4	-0.01	-
Interest & Investment Income	4.11	3.07	0.33	0	-
Currency Exchange Gain (Loss)	-	-	-0.06	-	-
Other Non Operating Income (Expenses)	0.21	-0.48	-0.22	-	-
Pretax Income	-50.53	-43.82	-31.25	-5.31	-0.21
Income Tax Expense	0.04	-	-	-	-
Net Income	-50.57	-43.82	-31.25	-5.31	-0.21
Net Income to Common	-50.57	-43.82	-31.25	-5.31	-0.21
Shares Outstanding (Basic)	421	398	376	277	104
Shares Outstanding (Diluted)	421	398	376	277	104
Shares Change (YoY)	5.79%	5.83%	36.09%	165.94%	-
EPS (Basic)	-0.12	-0.11	-0.08	-0.02	-0.00
EPS (Diluted)	-0.12	-0.11	-0.08	-0.02	-0.00
Free Cash Flow	-44.73	-55.07	-94.35	-11.77	-0.22
Free Cash Flow Per Share	-0.11	-0.14	-0.25	-0.04	-0.00
Gross Margin	84.30%	57.31%	43.73%	-	-
Operating Margin	-1088.90%	-4423.04%	-1152.91%	-	-
Profit Margin	-1018.90%	-4241.63%	-1166.05%	-	-
Free Cash Flow Margin	-901.17%	-5331.17%	-3520.60%	-	-
EBITDA	-46.59	-41.62	-29.15	-4.73	-
D&A For EBITDA	7.45	4.07	1.75	0.57	-
EBIT	-54.04	-45.69	-30.9	-5.3	-0.21

Source: S&P Global Market Intelligence. Standard template. Financial Sources.